Arrowhead Pharmaceuticals Faces Pivotal Regulatory Week

Investors in Arrowhead Pharmaceuticals are bracing for significant volatility as the biotechnology firm approaches two major regulatory events that could dramatically influence its valuation. The company stands at a critical juncture with an imminent FDA verdict on its drug Plozasiran while simultaneously unveiling groundbreaking cardiovascular data for Zodasiran.

Cardiovascular Breakthroughs and Regulatory Milestones

While the November 18 FDA decision regarding Plozasiran dominates investor attention, Arrowhead is making substantial progress in other therapeutic areas. Today, during the American Heart Association’s Scientific Sessions, the company revealed innovative study designs for Zodasiran targeting both adolescent and adult populations. This development positions Arrowhead’s cardiovascular portfolio as a potential second revenue stream alongside its established liver disease treatments.

The Plozasiran approval decision represents a gateway to the lucrative market for treating familial chylomicronemia, a rare genetic disorder. Beyond this initial application, Phase 3 trials exploring additional indications are progressing rapidly and expected to complete patient recruitment before year-end.

Expanding Pipeline and Strategic Alliances

Arrowhead’s recent presentation at the Liver Meeting 2025 featured comprehensive Fazirsiran data for addressing Alpha-1-Antitrypsin deficiency, demonstrating the company’s continued expansion beyond its core focus areas. The biotechnology firm’s business development efforts have yielded significant returns, evidenced by its recent licensing agreement with Novartis that generated an immediate $200 million payment with potential milestone payments reaching $2 billion.

Should investors sell immediately? Or is it worth buying Arrowhead?

The company continues to broaden its therapeutic reach with new clinical trials targeting neurodegenerative conditions and promising early-stage programs addressing obesity. Even ongoing patent disputes with Ionis Pharmaceuticals appear to have minimal impact on investor confidence, given the fundamental strength of Arrowhead’s RNAi portfolio.

Market Performance and Upcoming Catalysts

Financial markets have responded positively to these developments throughout 2025, with Arrowhead shares delivering an impressive 77% gain year-to-date, recently trading at €33.95. Despite some recent consolidation, the upward trend remains intact, with the stock hovering approximately 8% below its all-time peak of €36.98.

All attention will shift to the company’s annual financial results scheduled for release on November 25. Market participants will be watching closely to determine whether the financial performance can match the clinical successes. The coming fortnight will prove decisive in establishing whether Arrowhead can maintain its current momentum or requires a period of consolidation.